Patents by Inventor Wael Salameh

Wael Salameh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prognostic assays for maintenance hemodialysis patients
    Patent number: 11137410
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: October 5, 2021
    Assignees: Quest Diagnostics Investments LLC, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zedeh, Michael P. Caulfield, Wael A. Salameh
  • PROGNOSTIC ASSAYS FOR MAINTENANCE HEMODIALYSIS PATIENTS
    Publication number: 20200132702
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Applicants: Quest Diagnostics Investments LLC, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
    Inventors: Kamyar Kalantar-Zedeh, Michael P. Caulfield, Wael A. Salameh
  • ORAL PHARMACEUTICAL PRODUCTS AND METHODS OF USE COMBINING TESTOSTERONE ESTERS WITH HYPOLIPIDEMIC AGENTS
    Publication number: 20200016172
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 16, 2020
    Inventors: Wael SALAMEH, Panayiotis CONSTANTINIDES
  • Prognostic assays for maintenance hemodialysis patients
    Patent number: 10473675
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 12, 2019
    Assignees: Quest Diagnostics Investments Incorporated, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
  • Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
    Patent number: 10245273
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Wael Salameh, Panayiotis Constantinides
  • PROGNOSTIC ASSAYS FOR MAINTENANCE HEMODIALYSIS PATIENTS
    Publication number: 20170343568
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Application
    Filed: April 7, 2017
    Publication date: November 30, 2017
    Applicants: Quest Diagnostics Investments Incorporated, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
  • Prognostic assays for maintenance hemodialysis patients
    Patent number: 9638705
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: May 2, 2017
    Assignees: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED, LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
  • ORAL PHARMACEUTICAL PRODUCTS AND METHODS OF USE COMBINING TESTOSTERONE ESTERS WITH HYPOLIPIDEMIC AGENTS
    Publication number: 20160317553
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Application
    Filed: December 24, 2014
    Publication date: November 3, 2016
    Applicant: CLARUS THERAPEUTICS, INC.
    Inventors: Wael Salameh, Panayiotis Constantinides, I
  • PROGNOSTIC ASSAYS FOR MAINTENANCE HEMODIALYSIS PATIENTS
    Publication number: 20120103072
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Application
    Filed: October 27, 2011
    Publication date: May 3, 2012
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh
  • METHOD FOR DIAGNOSING LIVER FIBROSIS
    Publication number: 20110111430
    Abstract: Provided herein are methods and devices for nonsurgically predicting, diagnosing, and monitoring liver fibrosis in an individual. Methods utilize biomarkers, age and sex to determine a diagnostic score. The diagnostic score is then used to predict, diagnose, or assess liver fibrosis in the individual.
    Type: Application
    Filed: November 10, 2009
    Publication date: May 12, 2011
    Inventors: Ke X. Zhang, Wael A. Salameh